首页> 外文期刊>海南医科大学学报(英文版) >The impact analysis of the oxidative stress injury and inflammatory factor level for ticagrelor assisted PCI in the treatment the elderly patients with ST segment elevation acute myocardial infarction
【24h】

The impact analysis of the oxidative stress injury and inflammatory factor level for ticagrelor assisted PCI in the treatment the elderly patients with ST segment elevation acute myocardial infarction

机译:替卡格雷辅助PCI对老年ST段抬高急性心肌梗死患者氧化应激损伤和炎症因子水平的影响分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To investigate the effect of ticagrelor assisted PCI in treatment the elderly patients with acute ST elevation myocardial infarction (STEMI) on oxidative stress and inflammatory factor level.Methods:A total of 100 cases elderly patients with STEMI were selected that they were being treated with PCI. According to the digital list method was divided into the study group and control group, and 50 cases in each group. The control group was treated with PCI and the strong heart, anticoagulation, vasodilation, prevention of infection and other comprehensive treatment of myocardial infarction, the study group were given ticagrelor treatment which was based on the comprehensive treatment of myocardial infarction. The level change were compared that oxidative stress index (MDA), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) activity and inflammatory factor hypersensitive C reactive protein (hs-CRP), N-terminal pro brain natriuretic peptide (NT-proBNP) and interleukin -6 (IL-6) between the two groups in before treatment (T0), treatment with 7 d (T1), 14 d (T2), 30 d (T3).Results:(1)There was no significant difference in serum MDA, GSH-Px and SOD levels between the two groups in the T0. Two groups serum MDA level were higher than theT0, and the GSH-Px and SOD levels were lower than the T0 after operation in the T1.And the serum MDA level were lower than T0, T1, GSH-Px and SOD levels were higher than T0, T1in the T2, T3.The T3 serum MDA level was lower than T2, GSH-Px and SOD levels were higher than T2.Even the serum MDA was significantly lower than the control group T1, T2, T3 and the GSH-Px and SOD were higher than those of the control group T1, T2, T3 at the study groupT1, T2, T3, the difference was statistically significant. (2)There was no significant difference in T0 of the serum hs-CRP, IL-6 and NT-proBNP levels between the two groups. Two groups serum hs-CRP, IL-6 and NT-proBNP level were higher than the T0 after operation in the T1.And the serum hs-CRP, IL-6 and NT-proBNP levels were higher than T0, T1in the T2, T3.The T3 serum hs-CRP, IL-6 and NT-proBNP levels were lower than T2.and that the serum hs-CRP, IL-6 and NT-proBNP levels were significantly lower than the control group T1, T2, T3 at the study groupT1, T2, T3, so the difference was statistically significant.Conclusion:The treatment method will be able to reduce oxidative stress injury and effectively control the inflammatory response that ticagrelor assisted PCI in treatment the elderly patients with acute ST elevation myocardial infarction (STEMI).
机译:目的:探讨替卡格雷辅助PCI治疗老年急性ST段抬高型心肌梗死(STEMI)对氧化应激和炎性因子水平的影响。方法:选取100例老年STEMI患者进行治疗与PCI。根据数字表法将其分为研究组和对照组,每组50例。对照组给予PCI,强心,抗凝,血管舒张,预防感染等多种心肌梗死综合治疗,研究组给予替加格雷洛治疗,以心肌梗死综合治疗为基础。比较了氧化应激指数(MDA),谷胱甘肽过氧化物酶(GSH-Px),超氧化物歧化酶(SOD)活性和炎症因子超敏C反应蛋白(hs-CRP),N端脑钠素(NT-两组之间在治疗前(T0),7 d(T1),14 d(T2),30 d(T3)治疗前proBNP)和白介素-6(IL-6)。结果:(1)无T0两组之间的血清MDA,GSH-Px和SOD水平有显着差异。两组T1术后血清MDA高于T0,GSH-Px和SOD低于T0,血清MDA低于T0,T1,GSH-Px和SOD高于T0。 T0,T1在T2,T3中.T3的血清MDA水平低于T2,GSH-Px和SOD均高于T2,甚至血清MDA显着低于对照组T1,T2,T3和GSH-Px在研究组T1,T2,T3中,SOD和SOD均高于对照组T1,T2,T3,差异有统计学意义。 (2)两组血清hs-CRP,IL-6和NT-proBNP水平的T0无明显差异。两组T1术后血清hs-CRP,IL-6和NT-proBNP水平高于T0,而T2组血清hs-CRP,IL-6和NT-proBNP水平高于T0,T1, T3.T3血清hs-CRP,IL-6和NT-proBNP水平低于T2,并且血清hs-CRP,IL-6和NT-proBNP水平显着低于对照组T1,T2,T3结论:该治疗方法能够减轻氧化应激损伤,并有效控制替卡格雷治疗PCI对老年急性ST段抬高型心肌梗死患者的炎症反应,具有统计学意义。 (STEMI)。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2017年第11期|17-20|共4页
  • 作者单位

    Department of Coronary Heart Disease, Cardiovascular and Cerebrovascular Disease Hospital in Qinghai Province, Xining, Qinghai, 810012 China;

    Department of Coronary Heart Disease, Cardiovascular and Cerebrovascular Disease Hospital in Qinghai Province, Xining, Qinghai, 810012 China;

    Department of Coronary Heart Disease, Cardiovascular and Cerebrovascular Disease Hospital in Qinghai Province, Xining, Qinghai, 810012 China;

    Department of Coronary Heart Disease, Cardiovascular and Cerebrovascular Disease Hospital in Qinghai Province, Xining, Qinghai, 810012 China;

    Department of Clinical Laboratory, Cardiovascular and Cerebrovascular Disease Hospital in Qinghai Province, Xining, Qinghai, 810012 China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号